epocrates

Conference Highlights: The American Diabetes Association’s 84th Scientific Sessions

June 27, 2024

The American Diabetes Association hosted its 84th Scientific Sessions in Orlando, FL, from June 21-24, 2024. Below are selected highlights of the research presented at the meeting.

Continuous glucose monitoring improves glycemic control in T2DM patients not using insulin

In this large, real-world study of adults with suboptimally controlled T2DM not using insulin, Dexcom continuous glucose monitoring (CGM) use was associated with meaningful improvements in glycemic control over 12 months. Read more.

Semaglutide cuts kidney-disease, CV events in T2DM patients

Findings from the FLOW trial, the first dedicated kidney outcomes trial with a glucagon-like peptide-1 (GLP-1) receptor agonist, show that semaglutide use significantly reduced the risk of major kidney disease events and cardiovascular outcomes in patients with T2DM and chronic kidney disease. Read more.

Screening for hypercortisolism may be key to managing difficult-to-treat T2DM

Nearly one in four people with difficult-to-treat T2DM may have hypercortisolism, according to data from the CATALYST study, and may be a key factor to address in order to effectively manage T2DM. Read more.

Tirzepatide significantly improves sleep apnea and cardiovascular outcomes

SURMOUNT-OSA trial results showed that tirzepatide use in patients with obstructive sleep apnea and obesity resulted in improvements in sleep apnea severity and related metabolic issues, including body weight and systolic BP. Read more.

Semaglutide improves symptoms in men, women with HFpEF

STEP trial results show that semaglutide reduced body weight to a greater extent in women, and produced similar improvements in HF-related symptoms, physical limitations, and exercise function, regardless of sex, in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) with or without diabetes. Read more.

Fenofibrate may reduce progression of diabetic retinopathy

Fenofibrate, a drug used to reduce blood lipid levels, reduced progression of diabetic retinopathy compared with placebo among participants with early retinal changes, according to findings from the LENS trial. This is the first large-scale trial designed to investigate the effect of fenofibrate on eye outcomes in people with early diabetic retinopathy. Read more.

Inhaled insulin meets primary efficacy endpoints in T1DM study

INHALE-3, a phase 4, randomized controlled trial, examined the use of inhaled insulin in adults with T1DM and found it to be safe and efficacious, suggesting inhaled insulin may be a viable alternative to an insulin pump. Read more.